GlassScriptPhysician profile
Janet Bradshaw
NPI 1528025566
$272.54
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23.82 · 2020: $89.48 · 2021: $159.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $38.34 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $36.58 | 2021 | |
| Novo Nordisk INC | $31.23 | 2021 | |
| Mylan Specialty L.P. | $26.26 | 2019-2020 | |
| Abbvie INC. | $25.05 | 2021 | |
| Daiichi Sankyo INC. | $24.68 | 2021 | |
| Allergan, INC. | $19.03 | 2020 | |
| Amgen INC. | $16.49 | 2021 | |
| Eisai INC. | $15.73 | 2020 | |
| Janssen Pharmaceuticals, INC | $14.05 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $13.23 | 2020 | |
| Novartis Pharmaceuticals Corporation | $11.87 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janet Bradshaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.